SCHEMBL3626326

SCHEMBL3626326

CCOC(=O)C(CC=CC#N)C(=O)OCC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
TSHR P16473 2/20 0.36
CYP2C9 P11712 1/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
TDP1 Q9NUW8 4/20 0.35
HCAR2 Q8TDS4 1/20 0.34
HTT P42858 2/20 0.34
LMNA P02545 2/20 0.34
NPSR1 Q6W5P4 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 1/20 0.33
HSD17B10 Q99714 1/20 0.32
ALOX15 P16050 1/20 0.31
MAPK1 P28482 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MGAM O43451 1/20 0.31
SI P14410 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3626324 1.00 ALDH1A1 (0.36) ALDH1A1TSHRCYP2C9MEN1KMT2A
SCHEMBL3627866 1.00 ALDH1A1 (0.36) ALDH1A1TSHRCYP2C9MEN1KMT2A
SCHEMBL3626300 0.78 ALDH1A1 (0.33) ALDH1A1
SCHEMBL21560 0.78 ALDH1A1 (0.33) ALDH1A1
SCHEMBL3027656 0.76 NR1I2 (0.42) ALDH1A1TSHRMEN1KMT2ATDP1
SCHEMBL3027654 0.76 NR1I2 (0.42) ALDH1A1TSHRMEN1KMT2ATDP1
SCHEMBL16213944 0.76 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ATDP1HCAR2
SCHEMBL8990247 0.73 ALDH1A1 (0.43) ALDH1A1CYP2C9MEN1KMT2ATDP1
SCHEMBL11342973 0.73 ALDH1A1 (0.40) ALDH1A1TSHRCYP2C9MEN1KMT2A
SCHEMBL28912266 0.73 MGAM (0.43) ALDH1A1TSHRCYP2C9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781586-B2 Metathesis catalysts HOFFMAN-LA ROCHE INC. (US) 2010-08-24 US disclosed
EP-2044095-B1 NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS HOFFMANN LA ROCHE (CH) 2009-08-26 EP disclosed
EP-2044095-A1 NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METAHESIS REACTIONS F. Hoffmann-Roche AG (CH) 2009-04-08 EP disclosed
US-20080021219-A1 Metathesis Catalysts HOFFMANN-LA ROCHE INC. 2008-01-24 US disclosed
WO-2008000644-A1 NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METAHESIS REACTIONS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021219-A1 Metathesis Catalysts MTX1, MTX2, MLX ALDH1A1 2087/4885TSHR 2244/4885CYP2C9 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.